logo
Hospices need long-term funding plan, minister says

Hospices need long-term funding plan, minister says

Yahoo23-07-2025
Financially struggling hospices need a long-term funding plan rather than "sticking plaster" solutions, a government health minister has said.
Labour Minister of State for the Department of Health and Social Care Stephen Kinnock last week announced £75 million to be shared by 170 hospices across the country.
Unlike the NHS, hospices are not fully funded by the state and rely on charity contributions for about two thirds of their funding, with the sector reporting an estimated shortfall of £60m last financial year.
Speaking at Wigan & Leigh Hospice in Greater Manchester, which received £500,000 from the funding pool, Kinnock said the government needed to cover a bigger portion of the cost.
"We do warmly welcome the way that people step up and get involved in supporting their local hospice, but I absolutely recognise that we, the Department for Health and Social Care, we need to step up and do our bit," he said.
The £75 million is in addition to a £25 million package the government distributed in February.
Hospices in the north west of England provide end-of-life and palliative care for some 23,000 people in the region, with demand and costs continuing to rise.
Geoff Crook, 68, had been receiving care at Wigan & Leigh Hospice earlier this month alongside his wife Margaret, allowing him to be by her side for her final moments.
"I don't think we would have been able to cope if we hadn't had anything like this, I really don't" he said.
Wigan & Leigh Hospice chief executive Jo Carby said the £500,000 would be used to fix the building's leaking roof and to put in a new heating system and memory garden.
But she said it was "not enough" and that hospices needed a longer-term solution.
"Everyone's struggling for money essentially in our borough and it is unfair for us to be asking the people of Wigan to be spending more of their money when they already have less to spend in order to keep the hospice going," she said.
Kinnock said the government was currently negotiating how much funding would be allocated to palliative and end-of-life care in its three-year-spending review settlement.
He said: "As soon as we have that I want to see that long-term plan to take us at least through to the end of this parliament.
Kinnock said the government was determined to find "long-term solutions".
"I have made it very clear to my team of officials in [the Department] that I don't want another last-minute scramble at the end of the financial year to, with a sticking plaster, solve a problem for the short term," he said.
Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
More on this story
Campaigners warn NHS 'cannot afford hospice cuts'
Hospice fears pre-Christmas funding plans shelved
Campaigner takes hospice petition to Downing Street
Hospices facing funding crisis
Related internet links
Department of Health & Social Care
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy' Rating
UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy' Rating

Yahoo

time36 minutes ago

  • Yahoo

UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy' Rating

Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a 'Buy' rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 sales guidance. The biopharmaceutical company is facing weakness in its diagnostic segment. However, the weakness has not altered UBS's positive stance on the company. That's because the company is experiencing robust growth, with its MedTech division recording 12.2% organic growth in the second quarter, higher than the consensus estimate of 11.2%. In addition, UBS is buoyed by Abbott's 6.9% organic sales growth or 7.5% on excluding COVID diagnostics. The research firm expects robust growth in other segments, including the MedTech pipeline, to offset weakness in the diagnostic segment. Abbott Laboratories (NYSE:ABT) is a global healthcare company focused on creating life-changing technologies and products that span diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It is focused on improving health and well-being across all stages of life through innovative solutions and a commitment to accessibility. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best 52-Week High Stocks to Buy Now and 10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Raccoons could become UKs next invasive pest threat
Raccoons could become UKs next invasive pest threat

Yahoo

timean hour ago

  • Yahoo

Raccoons could become UKs next invasive pest threat

Raccoons could become the UK's next invasive pest threat. The British Pest Control Association (BPCA) has identified the species as a growing concern, noting that raccoons are already well-established pests in parts of Europe and could quickly adapt to UK environments if introduced. Niall Gallagher, technical manager at the BPCA, said: "Raccoons were imported into Germany from North America during the 1930s and rapidly became established across central Europe. "What we've learned from this is that once established, raccoons can thrive in our natural environments." While there is no evidence of a breeding population in the UK, raccoons have been identified by the Non-Native Species Secretariat (NNSS) as one of the top 20 species most likely to become invasive over the next decade. Raccoons can live for up to four years in the wild and pose risks to both property and wildlife. They also carry diseases and parasites that can be harmful to humans.

Wegovy and beyond: Will weight-loss drugs change the way people look at obesity?
Wegovy and beyond: Will weight-loss drugs change the way people look at obesity?

Yahoo

timean hour ago

  • Yahoo

Wegovy and beyond: Will weight-loss drugs change the way people look at obesity?

Wegovy, the blockbuster weight-loss drug, is now available in Singapore more than two years after it was approved by the Health Sciences Authority. But its arrival here sparks a deeper conversation about who should take it, how it makes us rethink obesity and weight loss, and whether weight-loss drugs are a magic bullet. Earlier in July, pharmaceutical firm Novo Nordisk, which makes Wegovy, announced in a statement that the injectable drug is now available with prescription from any licensed physician at hospitals and clinics across Singapore. The global hype around Wegovy, which is made for weight loss, stemmed from Ozempic, which was created as an anti-diabetic drug. The latter garnered a lot of attention on social media a few years ago after its users, who weren't all diabetics, showed off their considerable weight loss. What connects Wegovy and Ozempic – besides both being made by Novo Nordisk – is that they contain the active ingredient semaglutide. Mimicking the natural hormone glucagon-like peptide-1, semaglutide regulates blood sugar levels, curbs the appetite and induces the sensation of fullness. One of the differences? Wegovy has a higher maximum dosage of 2.4mg than Ozempic's 2mg. While the benefits have been laid out, what should those considering Wegovy look out for? To answer these questions on this episode of The Usual Place, I have: Senior consultant endocrinologist Dr Sue-Anne Toh from Novi Health, a specialist medical clinic and health-tech company. She has more than 20 years of experience in internal medicine, diabetes, and metabolic health. Her patient Farhan Hanis, a 26-year-old university student and a former plus-sized model. He started on Wegovy about two months ago. General practitioner Dr Bosty Chan, who co-founded health telemedicine providers Sire and Dame, which offers weight management as part of a suite of services. Tune in at 12pm SGT/HKT to watch the stream, and share your thoughts on our revamped YouTube channel. Follow The Usual Place Podcast live at noon every Thursday and get notified for new episode drops: Channel: Apple Podcasts: Spotify: YouTube: Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store